GPGI, Inc. Class A (GPGI)
Live price chart, market sentiment, and community perspectives for GPGI, Inc. Class A (NYSE: GPGI).
Live price chart, market sentiment, and community perspectives for GPGI, Inc. Class A (NYSE: GPGI).
On our desk, we are viewing the rebranding of CompoSecure to GPGI in January 2026 as a pivotal shift into a multi-industry platform strategy. With Dave Cote at the helm, the market is trying to price whether GPGI can truly function as a disciplined compounder or if it will remain valued like an average industrial tech company. The valuation sitting at around 9.7x 2026 EV/EBITDA leaves room for expansion if execution matches guidance.
From a hedge fund PM perspective, the Q2 results present a bifurcated picture. While GAAP net income swung into positive territory at $50.3 million, pro forma adjusted net sales dropped 4% to $473.2 million and EBITDA fell 13% due to softness at Husky. Management is reiterating their full-year guidance of $550 to $610 million in pro forma adjusted EBITDA, but macroeconomic uncertainty requires a cautious stance.
Looking at the Q2 2026 10-Q filing, the dilution impact is substantial. Shares outstanding jumped to 289.9 million at June 30, 2026, compared to 126.9 million at the end of December 2025, driven by the Husky transaction and PIPE issuances. Existing holders should carefully monitor how this massive share expansion affects per-share compounding over the next several quarters, despite the headline GAAP net income of $50.3 million.
As a risk manager tracking alternative data, AltIndex metrics score GPGI at 53/100, a clear hold signal. Over the past 90 days, core alternative data signals—including employment, web traffic, and brand indicators—have remained completely steady without moving more than 5%. This reflects a lack of near-term speculative momentum, keeping the stock range-bound between $12 and $26.
As a bio-analyst translating tech execution metrics to capital markets, I note that the Resolute Operating System (ROS) deployment is accelerating across both CompoSecure and Husky. The market wants to see if this operational framework can consistently drive the projected $275 to $325 million in pro forma adjusted free cash flow, especially given ongoing foreign exchange headwinds and lower volumes at Husky.
Explore plasma cleansing, somatic organ swaps, and BCI.